| scholarly article | Q13442814 |
| P50 | author | Matthew C Pickering | Q55692581 |
| Marina Botto | Q56247130 | ||
| P2093 | author name string | H Terence Cook | |
| Danielle Paixão-Cavalcante | |||
| Marina Botto | |||
| Steven Hanson | |||
| P2860 | cites work | Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice | Q24651118 |
| Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts | Q31034100 | ||
| Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. | Q33338223 | ||
| Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains | Q33375335 | ||
| Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway | Q33403738 | ||
| Factor H-related protein-5: a novel component of human glomerular immune deposits | Q34107748 | ||
| Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice | Q34537391 | ||
| Structural transitions of complement component C3 and its activation products | Q35544520 | ||
| Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis | Q36231096 | ||
| New approaches to the treatment of dense deposit disease | Q36860946 | ||
| Complement factor I and cofactors in control of complement system convertase enzymes | Q40796156 | ||
| Characterization of factor H binding to human polymorphonuclear leukocytes. | Q41514083 | ||
| Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation | Q42828955 | ||
| Management of membranoproliferative glomerulonephritis type II with plasmapheresis. | Q44178408 | ||
| Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. | Q45079393 | ||
| The reaction mechanism of the internal thioester in the human complement component C4. | Q50335847 | ||
| Cleavage of membrane bound C3bi, an intermediate of the third component of complement, to C3c and C3d-like fragments by crude leucocyte lysosomal lysates and purified leucocyte elastase. | Q53944268 | ||
| Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H | Q57089510 | ||
| The physiological breakdown of the third component of human complement | Q71147196 | ||
| Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2 | Q73947390 | ||
| Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18) | Q74477297 | ||
| Mouse podocyte complement factor H: the functional analog to human complement receptor 1 | Q79896677 | ||
| The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy | Q80375869 | ||
| An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis | Q93856155 | ||
| P433 | issue | 10 | |
| P921 | main subject | Complement component 3 | Q14874319 |
| Complement component factor h | Q14911977 | ||
| P304 | page(s) | 1942-1950 | |
| P577 | publication date | 2009-05-02 | |
| P1433 | published in | Molecular Immunology | Q6895954 |
| P1476 | title | Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase | |
| P478 | volume | 46 |
| Q30409539 | A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors |
| Q51730313 | An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. |
| Q42625961 | An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. |
| Q37644173 | C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. |
| Q30415634 | Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis |
| Q34534879 | Complement factor H deficiency accelerates development of lupus nephritis |
| Q36907945 | Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy |
| Q33411137 | Complement regulation in renal disease models |
| Q26795441 | Complement regulation: physiology and disease relevance |
| Q37286653 | Dense deposit disease and C3 glomerulopathy |
| Q35124165 | Dense deposit disease. |
| Q36793448 | Detection of complement activation using monoclonal antibodies against C3d. |
| Q37017177 | Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. |
| Q40865063 | Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy |
| Q37499843 | Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies |
| Q36509318 | Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency |
| Q33419651 | Molecules Great and Small: The Complement System |
| Q33425891 | Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy |
| Q38088187 | Recent insights into C3 glomerulopathy |
| Q37260204 | Soluble CR1 therapy improves complement regulation in C3 glomerulopathy |
| Q34005720 | Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice |
Search more.